» Articles » PMID: 33148803

Advanced Fluorescence Microscopy Reveals Disruption of Dynamic CXCR4 Dimerization by Subpocket-specific Inverse Agonists

Overview
Specialty Science
Date 2020 Nov 5
PMID 33148803
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Although class A G protein-coupled receptors (GPCRs) can function as monomers, many of them form dimers and oligomers, but the mechanisms and functional relevance of such oligomerization is ill understood. Here, we investigate this problem for the CXC chemokine receptor 4 (CXCR4), a GPCR that regulates immune and hematopoietic cell trafficking, and a major drug target in cancer therapy. We combine single-molecule microscopy and fluorescence fluctuation spectroscopy to investigate CXCR4 membrane organization in living cells at densities ranging from a few molecules to hundreds of molecules per square micrometer of the plasma membrane. We observe that CXCR4 forms dynamic, transient homodimers, and that the monomer-dimer equilibrium is governed by receptor density. CXCR4 inverse agonists that bind to the receptor minor pocket inhibit CXCR4 constitutive activity and abolish receptor dimerization. A mutation in the minor binding pocket reduced the dimer-disrupting ability of these ligands. In addition, mutating critical residues in the sixth transmembrane helix of CXCR4 markedly diminished both basal activity and dimerization, supporting the notion that CXCR4 basal activity is required for dimer formation. Together, these results link CXCR4 dimerization to its density and to its activity. They further suggest that inverse agonists binding to the minor pocket suppress both dimerization and constitutive activity and may represent a specific strategy to target CXCR4.

Citing Articles

CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

Khunti N, Kumar M, Datta M, Harelimana J, Harms M, Albers D Int J Mol Sci. 2025; 26(5).

PMID: 40076664 PMC: 11899823. DOI: 10.3390/ijms26052024.


Regulation of CXCR4 function by S1P through heteromerization.

Kim H, Jeong J, Huh W Cell Commun Signal. 2025; 23(1):111.

PMID: 40012038 PMC: 11863771. DOI: 10.1186/s12964-025-02099-x.


Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.

Conflitti P, Lyman E, Sansom M, Hildebrand P, Gutierrez-de-Teran H, Carloni P Nat Rev Drug Discov. 2025; .

PMID: 39747671 DOI: 10.1038/s41573-024-01083-3.


The histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models.

Bekaddour N, Smith N, Caspar B, Grinberg S, Giorgiutti S, Rodeschini V Front Immunol. 2024; 15:1490593.

PMID: 39737176 PMC: 11682962. DOI: 10.3389/fimmu.2024.1490593.


Amylin receptor subunit interactions are modulated by agonists and determine signaling.

Gostynska S, Karim J, Ford B, Gordon P, Babin K, Inoue A bioRxiv. 2024; .

PMID: 39416010 PMC: 11482831. DOI: 10.1101/2024.10.09.617487.


References
1.
Pierce K, Premont R, Lefkowitz R . Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002; 3(9):639-50. DOI: 10.1038/nrm908. View

2.
Zirafi O, Kim K, Standker L, Mohr K, Sauter D, Heigele A . Discovery and characterization of an endogenous CXCR4 antagonist. Cell Rep. 2015; 11(5):737-47. DOI: 10.1016/j.celrep.2015.03.061. View

3.
Wescott M, Kufareva I, Paes C, Goodman J, Thaker Y, Puffer B . Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices. Proc Natl Acad Sci U S A. 2016; 113(35):9928-33. PMC: 5024644. DOI: 10.1073/pnas.1601278113. View

4.
Ueda H, Siani M, Gong W, Thompson D, Brown G, Wang J . Chemically synthesized SDF-1alpha analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes. J Biol Chem. 1997; 272(40):24966-70. DOI: 10.1074/jbc.272.40.24966. View

5.
Arimont M, Sun S, Leurs R, Smit M, de Esch I, de Graaf C . Structural Analysis of Chemokine Receptor-Ligand Interactions. J Med Chem. 2017; 60(12):4735-4779. PMC: 5483895. DOI: 10.1021/acs.jmedchem.6b01309. View